Invivo Therapeutics Holdings Corp (NVIV) Stock: What Does the Chart Say Thursday?

The market has been down on Invivo Therapeutics Holdings Corp (NVIV) stock recently. NVIV gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Invivo Therapeutics Holdings Corp has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NVIV!

See Full NVIV Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With NVIV Stock Today?

Invivo Therapeutics Holdings Corp (NVIV) stock is up 0.75% while the S&P 500 has fallen -0.52% as of 1:00 PM on Thursday, May 4. NVIV has risen $0.01 from the previous closing price of $1.33 on volume of 13,086 shares. Over the past year the S&P 500 is down -2.54% while NVIV has fallen -74.08%. NVIV lost -$6.83 per share in the over the last 12 months.

More About Invivo Therapeutics Holdings Corp

About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer Sc.D. Professor at Massachusetts Institute of Technology and Joseph P. Vacanti M.D. who then was at Boston Childrens Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015 the companys investigational Neuro-Spinal Scaffold received the 2015 Beckers Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge MA. For more details visit www.invivotherapeutics.com. About the Neuro-Spinal Scaffold Following acute spinal cord injury surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing thereby reducing post-traumatic cavity formation sparing white matter and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold an investigational device has received a Humanitarian Use Device HUD designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete AIS A traumatic acute spinal cord injury. Click Here to get the full Stock Report for Invivo Therapeutics Holdings Corp stock.